Lumos Pharma Inc. (LUMO)
Lumos Pharma Statistics
Share Statistics
Lumos Pharma has 8.65M shares outstanding. The number of shares has increased by 6.56% in one year.
| Shares Outstanding | 8.65M |
| Shares Change (YoY) | 6.56% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 25.08% |
| Shares Floating | 5.66M |
| Failed to Deliver (FTD) Shares | 2.45K |
| FTD / Avg. Volume | 2.38% |
Short Selling Information
The latest short interest is 54.33K, so 0.63% of the outstanding shares have been sold short.
| Short Interest | 54.33K |
| Short % of Shares Out | 0.63% |
| Short % of Float | 0.87% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.76 and the forward PE ratio is null. Lumos Pharma's PEG ratio is -0.06.
| PE Ratio | -0.76 |
| Forward PE | n/a |
| PS Ratio | 12.63 |
| Forward PS | null |
| PB Ratio | 0.95 |
| P/FCF Ratio | -0.83 |
| PEG Ratio | -0.06 |
Enterprise Valuation
Lumos Pharma has an Enterprise Value (EV) of -8.59M.
| EV / Sales | -4.19 |
| EV / EBITDA | 0.23 |
| EV / EBIT | 0.28 |
| EV / FCF | 0.28 |
Financial Position
The company has a current ratio of 5.69, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.69 |
| Quick Ratio | 5.69 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -124.64% and Return on Invested Capital is -132.61%.
| Return on Equity | -124.64% |
| Return on Assets | -83.75% |
| Return on Invested Capital | -132.61% |
| Revenue Per Employee | $68.37K |
| Profits Per Employee | $-1.13M |
| Employee Count | 30 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -29K |
| Effective Tax Rate | 0.09% |
Stock Price Statistics
The stock price has increased by 61.94% in the last 52 weeks. The beta is 0.33, so Lumos Pharma's price volatility has been higher than the market average.
| Beta | 0.33 |
| 52-Week Price Change | 61.94% |
| 50-Day Moving Average | 4.22 |
| 200-Day Moving Average | 3.1 |
| Relative Strength Index (RSI) | 55.58 |
| Average Volume (20 Days) | 102.98K |
Income Statement
In the last 12 months, Lumos Pharma had revenue of 2.05M and earned -34.03M in profits. Earnings per share was -4.18.
| Revenue | 2.05M |
| Gross Profit | 2.05M |
| Operating Income | -36.61M |
| Net Income | -34.03M |
| EBITDA | -36.57M |
| EBIT | -36.61M |
| Earnings Per Share (EPS) | -4.18 |
Balance Sheet
The company has 35.08M in cash and 585K in debt, giving a net cash position of 34.49M.
| Cash & Cash Equivalents | 35.08M |
| Total Debt | 585K |
| Net Cash | 34.49M |
| Retained Earnings | -161.52M |
| Total Assets | 17.46M |
| Working Capital | 10.77M |
Cash Flow
In the last 12 months, operating cash flow was -31.09M and capital expenditures 0, giving a free cash flow of -31.09M.
| Operating Cash Flow | -31.09M |
| Capital Expenditures | 0 |
| Free Cash Flow | -31.09M |
| FCF Per Share | -3.82 |
Margins
Gross margin is 100%, with operating and profit margins of -1785.18% and -1659.39%.
| Gross Margin | 100% |
| Operating Margin | -1785.18% |
| Pretax Margin | -1660.8% |
| Profit Margin | -1659.39% |
| EBITDA Margin | -1783.03% |
| EBIT Margin | -1785.18% |
| FCF Margin | -1516.09% |
Dividends & Yields
LUMO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -131.4% |
| FCF Yield | -120.05% |
Analyst Forecast
The average price target for LUMO is $8.62, which is 98.6% higher than the current price. The consensus rating is "Hold".
| Price Target | $8.62 |
| Price Target Difference | 98.6% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Mar 19, 2020. It was a backward split with a ratio of 1:9.
| Last Split Date | Mar 19, 2020 |
| Split Type | backward |
| Split Ratio | 1:9 |
Scores
| Altman Z-Score | -19.2 |
| Piotroski F-Score | 3 |